Dr. Vimal Mehta, CEO and Founder, BioXcel Therapeutics talks about using artificial intelligence approaches in the development of drugs.  BioXcel's two most advanced clinical development programs are (1) BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders like schizophrenia, bipolar disorder, Alzheimer's and opioid addiction and (2) BXCL701, an immuno-oncology agent designed for the treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXCel Therapeutics